title: Preincubation of Dacron grafts with recombinant tissue factor pathway inhibitor decreases their thrombogenicity in vivo.
abstract: BACKGROUND
  We have previously shown that preincubation of whole blood clots with recombinants tissue factor pathway inhibitor (rTFPI) attenuates clot-associated procoagulant activity assessed ex vivo. This study was undertaken to determine whether a single local application of rTFPI induces similar attenuation of the procoagulant activity on preclotted Dacron grafts implanted in an artery in vivo.
  
  
  METHODS
  Dacron grafts (4 mm x 4 cm long) were preclotted in porcine blood and incubated with either rTFPI (5 mg/ml) or arginine-phosphate buffer for 15 minutes. Grafts were implanted end-to-end in the femoral arteries of 10 pigs, with one rTFPI-treated and one buffer-treated graft implanted in each animal. Animals did not undergo anticoagulation either before or after graft implantation. Radiolabeled porcine fibrinogen was injected intravenously, and the grafts underwent perfusion for 1 hour. A subgroup of animals (n = 7) also had infusion of radiolabeled autologous platelets at the time of administration of radiolabeled fibrinogen.
  
  
  RESULTS
  Fibrin(ogen) deposition was decreased in rTFPI-treated grafts by 36% +/- 7% (mean +/- SEM) compared with buffer-treated grafts (p = 0.001). Platelet deposition was also reduced in the rTFPI-treated grafts by 31% +/- 15%, although the reduction did not reach statistical significance (p = 0.10). The extent of rTFPI-mediated attenuation of fibrin(ogen) versus platelet deposition varied independently among animals.
  
  
  CONCLUSIONS
  Clot-directed anticoagulant effects of rTFPI appear to be useful for substantially decreasing the thrombogenicity of Dacron grafts immediately after their implantation. Chronic studies to determine whether the decreases in thrombogenicity result in improved long-term graft patency appear warranted.
authors.affiliation: Department of Surgery, Washington University, St Louis, MO 63110, USA.
authors.forename: B G
authors.initials: BG
authors.lastname: Rubin
authors.forename: B
authors.initials: B
authors.lastname: Toursarkissian
authors.forename: D
authors.initials: D
authors.lastname: Petrinec
authors.forename: L Y
authors.initials: LY
authors.lastname: Yang
authors.forename: P R
authors.initials: PR
authors.lastname: Eisenberg
authors.forename: D R
authors.initials: DR
authors.lastname: Abendschein
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000000981:diagnostic imaging; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D004353:Drug Evaluation, Preclinical; D005263:Femoral Artery / Q000601:surgery; D005340:Fibrinogen / Q000008:administration & dosage; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D007205:Indium Radioisotopes; D008074:Lipoproteins / Q000627:therapeutic use*; D017713:Platelet Transfusion; D011093:Polyethylene Terephthalates / Q000009:adverse effects*; D011877:Radionuclide Imaging; D011994:Recombinant Proteins / Q000627:therapeutic use; D013552:Swine; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D007205:Indium Radioisotopes; D008074:Lipoproteins; D011093:Polyethylene Terephthalates; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D005340:Fibrinogen